TL;DR | The Highlights
- Life sciences organizations have spent years automating individual tasks. But automating more work doesn’t necessarily create a more connected, intelligent business.
- The shift toward agentic AI introduces a bigger opportunity: moving beyond isolated efficiencies to improve how information, decisions, and actions flow across the enterprise.
- RPA isn’t going away, nor should it. The real question is where rules-based automation still makes sense, where AI agents add value, and how the two can work together.
- Salesforce’s evolving AI and Data 360 capabilities are expanding what’s possible, but technology alone won’t resolve fragmented processes, inconsistent data, or unclear accountability.
- In a regulated industry, the ability to control and explain what AI does is just as important as what it can accomplish.
We’ve Automated the Tasks. Have We Improved the Process?
For years, automation has helped life sciences organizations reduce the manual work behind everything from supply chain operations and order management to customer service and regulatory documentation.
And for good reason. When a process is repetitive, predictable, and governed by clear rules, automating it can save time, reduce errors, and free employees to focus on higher-value work.
But there’s an important distinction between making individual tasks more efficient and making an entire business process work better.
An organization might have automated order lookups, case routing, document extraction, and invoice matching, yet its teams may still spend significant time tracking down information, reconciling conflicting records, and coordinating decisions across systems.
Each task is technically more efficient. The overall process? Not necessarily.
That’s the limitation many organizations need to confront as they move into the next generation of AI: automation can eliminate manual steps without eliminating the operational friction between them.
And with agentic AI now entering the enterprise, that distinction matters more than ever.
The Next Evolution Isn’t About Replacing Bots with Agents
The conversation around enterprise automation has changed considerably since the early days of robotic process automation (RPA).
What began as a way to execute repetitive, rules-based activities has expanded into intelligent document processing, predictive AI, sophisticated workflow orchestration, and now AI agents capable of interpreting context and taking actions within defined boundaries. But this evolution shouldn’t be mistaken for a straightforward replacement cycle.
RPA remains valuable for stable, deterministic tasks. APIs and integration platforms remain essential for reliable system-to-system communication. Traditional workflows continue to provide predictable execution, particularly where processes require strict controls.
AI agents introduce something different: the ability to interpret a situation, retrieve relevant context, determine an appropriate next step, and use authorized tools to help move work forward. The opportunity isn’t to replace every existing automation with an agent. It’s to understand how these capabilities can work together to support a more complete business process.
Consider a distributor contacting a life sciences organization about a delayed shipment.
Traditional automation might retrieve an order status, update a case, or send a predefined notification. But if the issue involves inventory availability, shipping exceptions, account commitments, or potential quality concerns, employees may still need to piece together information from several systems before determining what to do.
An AI agent, appropriately grounded in enterprise data and connected to authorized actions, could help assemble that context, identify the appropriate next step, and coordinate permitted parts of the response.
The value isn’t simply answering the question faster. It’s reducing the friction between understanding a problem and taking the right action.
That’s where the conversation should shift: from automating individual activities to improving how work moves across the business.
Your Automation Footprint Doesn’t Tell You How Ready You Are for AI
One of the more misleading indicators of AI readiness is how much automation an organization already has.
A large portfolio of bots and workflows may demonstrate years of investment in operational efficiency. It doesn’t necessarily indicate that the organization has the connected data, process visibility, or governance required to support agentic operations. In fact, years of incremental automation can sometimes conceal underlying fragmentation.
Consider the systems involved in a typical life sciences environment: ERP, CRM, quality management, clinical platforms, manufacturing systems, and external partner applications. Each may serve its purpose effectively while maintaining its own records, processes, and controls.
Automation can bridge gaps between these systems without resolving the underlying disconnects. That’s not inherently a failure. In many cases, those automations were sensible solutions to immediate business needs. But introducing agents into the same environment raises a different set of questions.
- Can the agent access the right information?
- Is that information current and trustworthy?
- Does it understand which system owns the authoritative record?
- Can it execute an action without creating conflicting updates?
- And who is accountable when a workflow crosses from an administrative task into a regulated process?
These aren’t simply integration questions. They’re questions about how the business operates. Before investing in another layer of AI, organizations should understand where existing automation supports a well-designed process and where it compensates for a fragmented one.
That distinction can reveal far more about AI readiness than the number of bots already in production.
Connected Data Is the Foundation. Connected Execution Is the Opportunity.
The Salesforce ecosystem has evolved significantly in how it supports this next phase of enterprise automation.
With Data 360, organizations can bring together relevant information from Salesforce and external systems through approaches that include data harmonization, retrieval, and zero-copy access. Agentforce can then use appropriately configured data, instructions, and actions to support business workflows. Integrating external models via the Model Context Protocol (MCP) presents yet another critical consideration regarding model connectivity and authorized enterprise data boundaries.
For life sciences organizations, Salesforce’s industry-specific capabilities also create opportunities across commercial operations, patient services, medical engagement, and clinical workflows. But it’s important not to confuse access to more data with a fully connected operating model.
An agent might have visibility into an order, customer history, and relevant product information. That doesn’t automatically mean it should be authorized to change an order, make a quality determination, or initiate a regulated process.
Those decisions depend on business rules, system ownership, workflow design, and the level of autonomy the organization is prepared to support. This is also where integration architecture continues to matter. Data 360 can help provide context, while APIs, MuleSoft, Salesforce Flow, and other orchestration capabilities can support reliable execution across systems.
The goal isn’t to make every system autonomous. Not yet at least. It’s to make the right information and actions available at the right point in the process, with the appropriate controls.
For organizations with significant existing technology investments, that’s an important distinction. Moving toward agentic operations doesn’t require abandoning the systems that already run the business. It requires being more intentional about how those systems work together.
In Life Sciences, Responsible AI Is an Operating Requirement
There’s a reason life sciences organizations can’t approach agentic AI exactly like every other industry.
A service inquiry might appear routine until it contains a potential adverse event. A product question might require approved medical information. A seemingly simple case update could affect a regulated record or trigger a quality workflow.
The consequences of an AI action depend heavily on the context in which it operates. That’s why governance can’t be treated as a final implementation step. Organizations need to establish which information an agent can access, which actions it can execute independently, when human review is required, and how its behaviour will be monitored and documented. These controls should reflect the actual risk of the workflow, not simply whether AI is involved.
For example, helping a service representative retrieve approved information presents a different risk profile from allowing an agent to independently classify a product complaint or influence a regulated quality decision.
Salesforce provides capabilities for permissions, grounding, monitoring, and auditability. But those capabilities must still be configured, tested, and governed against the organization’s specific processes and regulatory obligations.
The regulatory conversation is evolving alongside the technology. Recent FDA guidance and industry principles increasingly emphasize defining an AI system’s intended context of use and evaluating risk accordingly. For life sciences leaders, that reinforces an important principle: The measure of AI maturity isn’t how much autonomy an organization can introduce. It’s how confidently that autonomy can be governed.
Start with the Business Outcome, Not the Agent
With new AI capabilities arriving quickly, it’s tempting to begin by identifying where an agent could be deployed. A more productive starting point is identifying where the business is experiencing the greatest operational friction.
- Where do employees repeatedly reconcile information across systems?
- Which processes depend on multiple handoffs?
- Where are delays driven by incomplete context rather than the complexity of the work itself?
These are the areas worth investigating.
Customer and distributor service can be a useful example. A high volume of inquiries may require information from order management, inventory, CRM, and quality systems. Employees may spend more time assembling the full picture than addressing the actual issue.
Rather than beginning with the question, “Can an agent handle these inquiries?” consider what an improved service process should look like.
- Could teams resolve more inquiries without switching systems?
- Could information be surfaced earlier?
- Could routine requests be handled through approved actions while sensitive issues are escalated consistently?
From there, determine which capabilities are appropriate.
Some steps may remain rules-based. Others may benefit from better integration or workflow orchestration. Certain activities may be suitable for agent assistance, while higher-risk decisions continue to require human involvement.
Measure the impact against the original business problem: resolution times, unnecessary handoffs, manual reconciliation, exception rates, quality of service, and the effort required to maintain the process.
An agent that performs an impressive demonstration but adds another disconnected workflow isn’t necessarily progress. An agent that helps simplify how work gets done, while preserving accountability, is a much stronger investment.
The Future of Automation Is Bigger Than Automation
Life sciences organizations don’t need to start their modernization journeys over. Their existing investments in RPA, enterprise platforms, integrations, and workflow automation remain important parts of the technology landscape. But the next phase requires a broader perspective.
Rather than asking how many more activities can be automated, organizations should be asking how effectively their systems, employees, and AI can work together to deliver a business outcome.
That means looking beyond individual tasks to the data, decisions, dependencies, and controls that shape an entire process. It also means recognizing that agentic AI isn’t simply another efficiency tool. Introduced thoughtfully, it creates an opportunity to reconsider how work is organized, how decisions are supported, and where human expertise delivers the greatest value.
At Lane Four, we work with organizations to connect their Salesforce investments to broader business processes, bringing together enterprise architecture, data, automation, and AI with the operational realities that determine whether technology delivers lasting value.
Because the next chapter of modernization isn’t just about making technology do more. It’s about making the business work better. Need someone to chat through what that means for your business? Let’s chat.
Let's chat!
